The bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 has been previously identified as a more potent analog of dexrazoxane (ICRF-187), a drug used in clinical practice against anthracycline cardiotoxicity. However, the poor aqueous solubility of ICRF-193 has precluded its further in vivo development as a cardioprotective agent. To overcome this issue, water-soluble prodrugs of ICRF-193 were prepared, their abilities to release ICRF-193 were investigated using a novel UHPLC-MS/MS assay, and their cytoprotective effects against anthracycline cardiotoxicity were tested in vitro in neonatal ventricular cardiomyocytes (NVCMs). Based on the obtained results, the bis(2-aminoacetoxymethyl)-type prodrug GK-667 was selected for advanced investigations due to its straightforward synthesis, sufficient solubility, low cytotoxicity and favorable ICRF-193 release. Upon administration of GK-667 to NVCMs, the released ICRF-193 penetrated well into the cells, reached sufficient intracellular concentrations and provided effective cytoprotection against anthracycline toxicity. The pharmacokinetics of the prodrug, ICRF-193 and its rings-opened metabolite was estimated in vivo after administration of GK-667 to rabbits. The plasma concentrations of ICRF-193 reached were found to be adequate to achieve cardioprotective effects in vivo. Hence, GK-667 was demonstrated to be a pharmaceutically acceptable prodrug of ICRF-193 and a promising drug candidate for further evaluation as a potential cardioprotectant against chronic anthracycline toxicity.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Faculty of Pharmacy in Hradec Králové Charles University Akademika Heyrovského 1203 500 05 Hradec Králové Czech Republic

Faculty of Medicine in Hradec Králové Charles University Šimkova 870 500 03 Hradec Králové Czech Republic

Zobrazit více v PubMed

Nebigil CG, Desaubry L. Updates in anthracycline-mediated cardiotoxicity. Front. Pharmacol. 2018;9:1262. doi: 10.3389/fphar.2018.01262. PubMed DOI PMC

Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ. Res. 2016;118:1008–1020. doi: 10.1161/CIRCRESAHA.115.303633. PubMed DOI

Cvetkokic RS, Scott LJ. Dexrazoxane—a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005–1024. doi: 10.2165/00003495-200565070-00008. PubMed DOI

Sterba M, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox Signal. 2013;18:899–929. doi: 10.1089/ars.2012.4795. PubMed DOI PMC

Jirkovska-Vavrova A, et al. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol. Res. 2015;4:1098–1114. doi: 10.1039/C5TX00048C. DOI

Kollárová-Brázdová P, et al. Investigation of structure-activity relationships of dexrazoxane analogues reveals topoisomerase IIβ interaction as a pre-requisite for effective protection against anthracycline cardiotoxicity. J. Pharmacol. Exp. Ther. 2020;373:402–415. doi: 10.1124/jpet.119.264580. PubMed DOI

Martin E, et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009;255:72–79. doi: 10.1016/j.tox.2008.10.011. PubMed DOI

Hasinoff BB, Patel D, Wu X. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition. Toxicol. Appl. Pharmacol. 2020;399:115038. doi: 10.1016/j.taap.2020.115038. PubMed DOI

Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 1998;5:1–28. PubMed

Hasinoff BB, Herman EH. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol. 2007;7:140–144. doi: 10.1007/s12012-007-0023-3. PubMed DOI

Zhang S, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012;18:1639–1642. doi: 10.1038/nm.2919. PubMed DOI

Lyu YL, et al. Topoisomerase II beta-Mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839–8846. doi: 10.1158/0008-5472.CAN-07-1649. PubMed DOI

Deng S, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:842. doi: 10.1186/1471-2407-14-842. PubMed DOI PMC

Lencova-Popelova O, et al. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane. J. Mol. Cell. Cardiol. 2016;91:92–103. doi: 10.1016/j.yjmcc.2015.12.021. PubMed DOI

Bures J, et al. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. 2017;392:1–10. doi: 10.1016/j.tox.2017.09.012. PubMed DOI

Swift LP, et al. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother. Pharmacol. 2008;61:739–749. doi: 10.1007/s00280-007-0528-2. PubMed DOI

Reimerova P, et al. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. Sci. Rep. 2019;9:4524. doi: 10.1038/s41598-019-40928-5. PubMed DOI PMC

Narita T, et al. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine) Cancer Chemother. Pharmacol. 1991;28:235–240. PubMed

Takase, M., Narita, T. & Komatsu, T. Water soluble bis-dioxopiperazine derivatives. US Patent 5393889 (1995).

Jirkovsky E, et al. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. J. Pharmacol. Exp. Ther. 2018;364:433–446. doi: 10.1124/jpet.117.244848. PubMed DOI

Buss JL, Hasinoff BB. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) Arch. Biochem. Biophys. 1995;317:121–127. doi: 10.1006/abbi.1995.1143. PubMed DOI

Buss JL, Hasinoff BB. Metal ion-promoted hydrolysis of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and its one-ring open hydrolysis products to its metal-chelating active form. J. Inorg. Biochem. 1997;68:101–108. doi: 10.1016/S0162-0134(97)00080-9. DOI

Simunek T, et al. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur. J. Heart Fail. 2004;6:377–387. doi: 10.1016/j.ejheart.2003.05.003. PubMed DOI

Jirkovsky E, et al. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology. 2013;311:191–204. doi: 10.1016/j.tox.2013.06.012. PubMed DOI

25European Medicines Agency. Guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (2012). PubMed

Simunek T, et al. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br. J. Pharmacol. 2008;155:138–148. doi: 10.1038/bjp.2008.236. PubMed DOI PMC

Chan FK, Moriwaki K, De Rosa MJ. Detection of necrosis by release of lactate dehydrogenase activity. Methods. Mol. Biol. 2013;979:65–70. doi: 10.1007/978-1-62703-290-2_7. PubMed DOI PMC

Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods. 1983;64:313–320. doi: 10.1016/0022-1759(83)90438-6. PubMed DOI

Legrand C, et al. Lactate-Dehydrogenase (Ldh) Activity of the Number of Dead Cells in the Medium of Cultured Eukaryotic Cells as Marker. J. Biotechnol. 1992;25:231–243. doi: 10.1016/0168-1656(92)90158-6. PubMed DOI